FDA Clears Tarsus’ Xdemvy as First Treatment for Common Eyelid Disease
July 27, 2023
Source: drugdu
107
Patients with the eyelid disease Demodex blepharitis can now see a cure in Tarsus Pharmaceuticals’ Xdemvy, the first FDA-approved treatment for an ailment that affects some 25 million Americans.
The eye drops directly target Demodex mites, an ectoparasite infestation that causes the disease.
Tarsus expects Xdemvy, an eye drop formulation of pet flea and tick treatment lotilaner, to be available by the end of August. The company has already started marketing for the often-misdiagnosed disease with a campaign called “Don’t Freak Out. Get Checked Out," which launched in May.
And last year, the company started a marketing campaign called “Look at the Lids,” which encourages eye doctors to screen for the condition.
In two trials involving more than 833 patients, investigators testing the drug noted improvement in collarettes, which is the accumulation of the mite’s waste and eggs.
Before Xdemvy, the 1 in every 12 U.S. adults who suffer from the condition turned to tea tree oil and lid wipes, which don’t target the root cause of the disease.
Elsewhere, the company’s pipeline includes treatments for meibomian gland dysfunction, rosacea and Lyme disease.
Source: ophthalmologyTimes.com
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
